RIP1 inhibitory compounds and methods for making and using the same
AssigneeRigel Pharmaceuticals, Inc.
InventorsEsteban Masuda, Simon Shaw, Vanessa Taylor, Somasekhar Bhamidipati
Life of this patent
Estimating the term…
Abstract
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.
Claims13
A compound having the formula
- or a pharmaceutically acceptable salt thereof.
A compound which is:
A pharmaceutical composition, comprising a compound having the formula:
- or a pharmaceutically acceptable salt thereof, and
- at least one excipient.
A pharmaceutical composition, comprising a compound having the formula:
- and at least one excipient.
A method for treating a disease in a subject wherein the disease is a disease involving a receptor-interacting protein-1 (RIP1) kinase, comprising administering to the subject a therapeutically effective amount of the compound of the formula:
- wherein the disease involving the RIP1 kinase is psoriasis.
A method for treating a disease in a subject wherein the disease is a disease involving a receptor-interacting protein-1 (RIP1) kinase, comprising administering to the subject a therapeutically effective amount of the compound of the formula:
- wherein the disease involving the RIP1 kinase is rheumatoid arthritis.
A method for treating a disease in a subject wherein the disease is a disease involving a receptor-interacting protein-1 (RIP1) kinase, comprising administering to the subject a therapeutically effective amount of the compound of the formula:
- wherein the disease involving the RIP1 kinase is atopic dermatitis.
Dependencies are inferred from the claim text.